IL4 Androgen Deprivation Therapy for Prostate Cancer : A US Perspective

Androgen Deprivation Therapy for Prostate Cancer

Androgen Deprivation Therapy for Prostate Cancer

AN D R O G E N D E P R I V A T I O N t h e r a p y ( A D T ; h e r e i n defined as medical or surgical castration) is the cornerstone treatment of advanced prostate cancer. In 1941, Huggins and Hodges first noted the beneficial effects of castration and injection of estrogens in patients with metastatic prostate cancer. The biological basis of the effect of ADT, the almost ubiquitous expressio...

Androgen deprivation therapy for prostate cancer.

CONTEXT Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in US men. Androgen deprivation therapy (ADT), specifically surgical or medical castration, is the first line of treatment against advanced prostate cancer and is also used as an adjuvant to local treatment of high-risk disease. OBJECTIVE To review systematically the evidence on the risk...

Androgen Deprivation for Prostate Cancer

The beneficial effects of androgen deprivation on prostate cancer have been known for more than a half century, based on work demonstrating the androgen dependency of prostate tumor cells. Androgen deprivation therapy (ADT), initially in the form of bilateral orchiectomy, has accordingly long been a mainstay for the palliation of metastatic prostate cancer. For most of its history, concerns abo...

Androgen deprivation therapy for prostate cancer: not so simple.

P rostate cancer (PC) is the second most diagnosed visceral malignancy in men worldwide, with over 900 000 new diagnoses each year. Approximately 50% of patients treated in industrialized nations will receive androgen deprivation therapy (ADT) at some point in their lifetimes. The use of ADT as a treatment approach is likely to increase as new drug developments have focused on intensifying the ...